Status:
COMPLETED
Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
Lead Sponsor:
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
Conditions:
HIV Infections
Tuberculosis
Eligibility:
All Genders
13+ years
Brief Summary
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with projected rates of requirement for ARV therapy extending to more than 10...
Detailed Description
Well developed TB diagnostic testing, contact tracing, and treatment programs are key parts of the public health and health care infrastructure in many countries where HIV infection has resulted in a ...
Eligibility Criteria
Inclusion
- HIV-infected
Exclusion
- Receipt of ART within 90 days prior to study entry
- Diagnosis of active TB (pulmonary or extrapulmonary) within 90 days prior to study entry
- Receipt of 7 or more cumulative days of certain medications within 90 days prior to study entry. More information on this criterion can be found in the protocol.
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
801 Patients enrolled
Trial Details
Trial ID
NCT00865826
Start Date
December 1 2009
End Date
March 1 2011
Last Update
March 18 2015
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Gaborone Prevention/Treatment Trials CRS
Gaborone, Botswana
2
Molepolole Prevention/Treatment Trials CRS (Molepolole PTT CRS)
Molepolole, Botswana
3
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Manguinhos, Rio de Janeiro, Brazil
4
BJ Medical College CRS
Pune, Maharashtra, India, 411001